ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to Hold at Zacks Research

ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Roth Mkm initiated coverage on ARS Pharmaceuticals in a report on Tuesday, November 4th. They issued a “buy” rating and a $30.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.67.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $9.34 on Wednesday. The firm has a fifty day moving average price of $10.45 and a 200-day moving average price of $10.42. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51. The stock has a market cap of $923.26 million, a PE ratio of -11.53 and a beta of 0.79. ARS Pharmaceuticals has a 1 year low of $6.66 and a 1 year high of $18.90.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP lifted its position in ARS Pharmaceuticals by 37.8% during the 4th quarter. Rubric Capital Management LP now owns 6,200,000 shares of the company’s stock worth $72,230,000 after acquiring an additional 1,700,000 shares during the period. Aberdeen Group plc grew its position in ARS Pharmaceuticals by 14.8% during the 4th quarter. Aberdeen Group plc now owns 3,556,049 shares of the company’s stock worth $41,428,000 after purchasing an additional 459,027 shares during the period. Vanguard Group Inc. grew its holdings in ARS Pharmaceuticals by 7.3% during the third quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after acquiring an additional 237,630 shares during the period. State Street Corp increased its holdings in shares of ARS Pharmaceuticals by 11.3% during the 4th quarter. State Street Corp now owns 3,223,581 shares of the company’s stock valued at $37,555,000 after purchasing an additional 328,325 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in ARS Pharmaceuticals in the fourth quarter valued at $36,912,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.